Fig. 5: RA specifically inhibited SRC/AKT signaling pathways during osteoclastogenesis. | Cell Death & Disease

Fig. 5: RA specifically inhibited SRC/AKT signaling pathways during osteoclastogenesis.

From: Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells

Fig. 5

a RAW264.7 cells were treated with or without RANKL (50 ng/mL), RA (0.8 μM), or SC79 (25 μM) for 0, 10, or 30 min, respectively. Western blotting for p-AKT was analyzed with the cell lysates. b RAW264.7 cells were treated with or without RANKL (50 ng/mL), RA (0.8 μM), or SC79 (25 μM) for 0, 1, 3, or 5 days respectively. Western blotting for SRC was analyzed with the cell lysates. c RAW264.7 cells were treated with or without RA (0.8 μM) with the addition of RANKL (50 ng/mL) for 0, 10 or 30 min, respectively. Western blotting for MAPK and IκBα signaling pathways was analyzed with the cell lysates

Back to article page